Background
Therapeutic HIV vaccines in development aim to induce, mature and boost broadly neutralizing antibody (bnAb) responses in persons living with HIV (PLWH) on antiretroviral therapy (ART) with the potential goal of ART-free remission. Biomarkers are needed to assess such neutralizing responses. We developed and validated an assay to measure nascent bnAb activity using an indicator panel of pseudotyped HIV Envs sensitive to early bnAb intermediates and precursors. We examined the frequency of nascent bnAb activity in PLWH on ART and evaluated whether clinical parameters can distinguish persons with and without nascent bnAbs.
Methods
IgG was purified from plasma of 79 PLWH on ART with HIV RNA <50 copies/ml for at least 2 years. Prior to IgG purification, plasmas were spiked with anti-SIV Env mAb K11 to quantify the purification efficiency by assessing SIV neutralization. A panel of 9 pseudotyped HIV Envs was selected, sensitive to precursors and early variants of bnAbs targeting the CD4bs, V2 apex and V3-glycan epitopes. ID50 neutralization titers of >1:100 to one virus, or >1:50 to two viruses, or >1:25 to three viruses were considered evidence of nascent bnAb activity.
Results
24 (30%) donors showed evidence of nascent bnAb activity (Figure), with V3-glycan directed responses being the most prevalent. bnAb assessments were repeated at two timepoints (mean 5.8 years apart, range 4.3-6.9 years) for 9 donors. Eight donors tested negative for nascent bnAb activity at both timepoints, while one with detectable nascent bnAb activities retained multiple epitope specificities at both timepoints with no change in titers. There was no association between nascent bnAb activity and time since HIV diagnosis, CD4 nadir, history of opportunistic infection, time to ART initiation, history of any ART interruptions or virologic failure on ART. Multivariable logistic regression indicated that older age (>60 years vs <50 OR=11.1, 95% CI: 1.2-98.3, P=.03) and lower pre-ART peak viral load (<10,000 copies/ml OR=4.3, 95% CI 1.04-17.6, P=.04) were associated with detectable nascent bnAb activity.
Conclusions
We detected nascent bnAb activity in 30% of PLWH on ART. The activity was associated with age >60 years and peak pre-ART HIV RNA <10,000; and was stable over time among those retested. The nascent bnAb assay panel used should be valuable for assessing whether HIV vaccine candidates in development can boost or broaden nascent bnAb activities in PLWH on ART.
Table or Figure
